Your browser doesn't support javascript.
The Israeli Experience with the "Green Pass" Policy Highlights Issues to Be Considered by Policymakers in Other Countries.
Waitzberg, Ruth; Triki, Noa; Alroy-Preis, Sharon; Lotan, Tomer; Shiran, Liat; Ash, Nachman.
  • Waitzberg R; Department of Health Care Management, Faculty of Economics & Management, Technische Universität, 10623 Berlin, Germany.
  • Triki N; Department of Health Policy and Management, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
  • Alroy-Preis S; The Smokler Center for Health Policy Research, Myers-JDC-Brookdale Institute, Jerusalem 91037, Israel.
  • Lotan T; Ministry of Health, Jerusalem 9101002, Israel.
  • Shiran L; Public Health Services, Ministry of Health, Jerusalem 9101002, Israel.
  • Ash N; Ministry of Public Security, Jerusalem 9103401, Israel.
Int J Environ Res Public Health ; 18(21)2021 Oct 26.
Article in English | MEDLINE | ID: covidwho-1488539
ABSTRACT
In the first half of 2021, Israel had been ahead of other countries concerning the speed of its rollout and coverage of COVID-19 vaccinations. During that time, Israel had implemented a vaccine certificate policy, the "Green Pass Policy" (GPP), to reduce virus spread and to allow the safe relaxation of COVID-19 restrictions in a time of great uncertainty. Based on an analysis of GPP regulations and public statements compiled from the Israeli Ministry of Health website, we describe the design and implementation of the GPP. We also look back and discuss lessons learned for countries that are considering a GPP policy, given the current upsurge of the Delta variant as of summer 2021. To reduce equity concerns when introducing a GPP, all population groups should be eligible for the vaccine (contingent on approval from the manufacturer) and have access to it. Alternatively, health authorities can grant temporary certificates based on a negative test. We also highlight the fact that in practice, there will be gaps between the GPP regulations and implementation. While some places might require a GPP without legal need, others will not implement it despite a legal obligation. The GPP regulations should have standardised epidemiological criteria, be implemented gradually, remain flexible, and change according to the epidemiological risks.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Year: 2021 Document Type: Article Affiliation country: Ijerph182111212

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Year: 2021 Document Type: Article Affiliation country: Ijerph182111212